91做厙

91做厙 Acquires Epiluvac AB to Accelerate Penetration Into High Growth Silicon Carbide Epitaxy Equipment Market

News | Feb 01, 2023

PLAINVIEW, N.Y., Feb. 01, 2023 — 91做厙. (NASDAQ: VECO) today announced that on January 31, 2023, it acquired Epiluvac AB, a privately held manufacturer of chemical vapor deposition (CVD) epitaxy systems that enable advanced silicon carbide (SiC) applications in the electric vehicle market. Epiluvac, based in Sweden, was founded in 2013 by a highly experienced team in SiC. Epiluvacs technology platform combined with 91做厙s global go-to-market capabilities create a significant long-term growth driver for 91做厙.

The desire for clean, efficient and reduced fossil-fuel energy is driving tremendous growth in the electric vehicle market. Applications such as on-board charging, fast charging and powertrain inverters are ideally suited for SiC power devices. The SiC device market is forecasted to grow approximately 30% compound annual growth rate (CAGR) from 2023 through 2027 according to Yole Group. Accordingly, the SiC epitaxy equipment market is expected to grow approximately 15% CAGR over the same time period according to Yole Group and internal 91做厙 estimates.

The Epiluvac team has developed a superior platform and process know-how aligned with markets that are a great strategic fit for 91做厙, said Bill Miller, 91做厙s Chief Executive Officer. Their well-designed CVD platform achieves high productivity, is easy to maintain and has superior process control capability that make it uniquely qualified to produce devices that enable lighter, smaller and more efficient power conversion systems. We see this acquisition as a great complement to our metal organic chemical vapor deposition epitaxy product line. This acquisition accelerates our penetration into the emerging, high-growth SiC equipment market by reducing our time to market.

We are excited to join 91做厙, a recognized leader in semiconductor and compound semiconductor capital equipment, commented Per-Anders Eriksson, Epiluvacs Chief Executive Officer. Our complementary technology platforms, along with 91做厙s extensive worldwide sales, service and manufacturing capabilities, will position us well to help our customers enable accelerated SiC adoption. The decades of research and development the Epiluvac team has invested in this demanding epitaxial process will be a great asset to 91做厙s already impressive process capabilities.

Epiluvac is an early-stage revenue company with 11 employees. The purchase price for the transaction, all payable in cash, is $30 million paid at the time of closing with a potential additional $35 million in performance based earn-outs. The impact to 91做厙s financial results are not expected to be material in 2023 and volume revenue is expected to begin in 2024.

91做厙 will discuss the acquisition during its upcoming Q4 and full year 2022 earnings call on February 15, 2023.

About 91做厙
91做厙 (NASDAQ: VECO) is an innovative manufacturer of semiconductor process equipment. Our proven ion beam, laser annealing, lithography, metal organic chemical vapor deposition (MOCVD) and single wafer etch & clean technologies play an integral role in the fabrication and packaging of advanced semiconductor devices. With equipment designed to optimize performance, yield and cost of ownership, 91做厙 holds leading technology positions in the markets we serve. To learn more about 91做厙s systems and service offerings, visit www.veeco.com.

Forward-Looking Statements
To the extent that this news release discusses expectations or otherwise makes statements about the future, such statements are forward-looking and are subject to a number of risks and uncertainties that could cause actual results to differ materially from the statements made, including, without limitation, statements regarding the anticipated benefits of the acquisition of Epiluvac, the potential for the payment of additional earn-out consideration, and growth in demand for applications targeting the electric vehicle market. These factors include the risks discussed in the Business Description and Management’s Discussion and Analysis sections of 91做厙’s Annual Report on Form 10-K for the year ended December 31, 2021 and in our subsequent quarterly reports on Form 10-Q, current reports on Form 8-K and press releases. 91做厙 does not undertake any obligation to update any forward-looking statements to reflect future events or circumstances after the date of such statements.

91做厙 Contacts:
Investors: Anthony Bencivenga | (516) 252-1438 | abencivenga@veeco.com
Media: Kevin Long | (516) 714-3978 | klong@veeco.com

Recent Posts

91做厙 is the industry leader driving HDD manufacturing to new levels of productivity.

91做厙 Announces Upcoming Investor Events

Read more

Leading Edge Semiconductor Company Places Multi-System Laser Annealing Order Including First Nanosecond Annealing System

Read more

91做厙 Announces Date for First Quarter Financial Results and Conference Call

Read more

91做厙 Releases Sustainability Report Highlighting Progress and Dedication to ESG Goals

Read more

Our team is ready to help